J Biol Chem, Vol. 274, Issue 36, 25708-25717, September 3, 1999
Caveolin-2 Localizes to the Golgi Complex but Redistributes to
Plasma Membrane, Caveolae, and Rafts when Co-expressed with
Caveolin-1*
Rosalia
Mora
,
Vera L.
Bonilha
,
Alan
Marmorstein
,
Philipp
E.
Scherer§¶,
Dennis
Brown
,
Michael P.
Lisanti**
, and
Enrique
Rodriguez-Boulan
§§
From the
Dyson Vision Research Institute, Department
of Ophthalmology, and Department of Cell Biology, Weill Medical College
of Cornell University, New York 10021, the
Renal Unit
and Department of Pathology, Massachusetts General Hospital and Harvard
Medical School, Boston, Massachusetts 02129, and the Departments of
** Molecular Pharmacology and § Cell Biology, Albert
Einstein College of Medicine, Bronx, New York 10461
 |
ABSTRACT |
We have characterized comparatively
the subcellular distributions of caveolins-1 and -2, their interactions
and their roles in caveolar formation in polarized epithelial cells. In
Fischer rat thyroid (FRT) cells, which express low levels of caveolin-2 and no caveolin-1, caveolin-2 localizes exclusively to the Golgi complex but is partially redistributed to the plasma membrane upon
co-expression of caveolin-1 by transfection or by adenovirus-mediated transduction. In Madin-Darby canine kidney (MDCK) cells, which constitutively express both caveolin-1 and -2, caveolin-2 localized to
both the Golgi complex and to the plasma membrane, where it co-distributed with caveolin-1 in flat patches and in caveolae. In FRT
cells, endogenous or overexpressed caveolin-2 did not associate with
low density Triton insoluble membranes that floated in sucrose density
gradients but was recruited to these membranes when co-expressed together with caveolin-1. In MDCK cells, both caveolin-1 and caveolin-2 associated with low density Triton-insoluble membranes. In FRT cells,
transfection of caveolin-1 promoted the assembly of plasma membrane
caveolae that localized preferentially (over 99%) to the basolateral
surface, like constitutive caveolae of MDCK cells. In contrast, as
expected from its intracellular distribution, endogenous or
overexpressed caveolin-2 did not promote the assembly of caveolae;
rather, it appeared to promote the assembly of intracellular vesicles
in the peri-Golgi area. The data reported here demonstrate that
caveolin-1 and -2 have different and complementary subcellular localizations and functional properties in polarized epithelial cells
and suggest that the two proteins co-operate to carry out specific as
yet unknown tasks between the Golgi complex and the cell surface.
 |
INTRODUCTION |
Plasmalemmal caveolae are specialized plasma membrane
microdomains, first discovered on the surface of endothelial cells (1) where they function in transport processes (2, 3) and then described in
a variety of cell types (4). By transmission electron microscopy,
caveolae can be distinguished by their characteristic morphology:
flask-shaped 60-90-nm vesicles located at or near the plasmalemma (1,
5). By rapid freeze, deep etch replica methods, caveolae are seen to be
coated cytoplasmically by a distinct striated filamentous coat, that
contains a 21-kDa protein, caveolin (4). Caveolin was also identified
as a component of post-Golgi vesicles, hence its other name VIP21
(vesicle integral protein of
21 kDa) (6).
Recently, a multigene family of caveolin-related proteins has been
identified (7). The original caveolin/VIP21 was renamed caveolin-1.
Caveolin-2, with 38% sequence identity and 58% similarity to
caveolin-1, has an overlapping tissue distribution with caveolin-1; both proteins are found as long (
) and short (
) isoforms lacking a few N-terminal amino acids (8-10). Caveolin-3 is muscle-specific (11, 12). The presence of caveolin-1 in the caveolar coat suggested
that it might be involved in the formation of caveolae. Indeed, recent
experiments in which caveolin-1 was transiently (13, 14) or permanently
(15, 16) transfected into caveolin-deficient cell lines have shown that
caveolin-1 promotes de novo formation of caveolae. In
vivo experiments have shown that the long (
) isoforms of the
two proteins can form homo- and hetero-oligomers during biosynthesis
(8-10, 17, 18) and that these oligomers are differentially transported
to the cell surface; whereas the smaller caveolin-1 and -2 hetero-oligomers are transported to the basolateral surface, the larger
caveolin-1 homo-oligomers are transported to the apical surface of
MDCK1 cells (8). The primary
determinants of oligomerization are in the protein moieties; however,
the cholesterol binding ability of caveolin-1 (19) and the attachment
of palmitoyl chains to the C-terminal region (20) does promote
additional clustering. Oligomers can be isolated from tissues taking
advantage of their insolubility in detergents, such as Triton X-100 and
CHAPS at 4 °C (6, 21). To date, the individual ability of
caveolins-1 and -2 to form detergent insoluble oligomers in
vivo has not been characterized because of their parallel tissue distribution.
Here we utilize an epithelial cell line (FRT) that expresses low levels
of caveolin-2 and, as shown before (15, 22), no caveolin-1, as a tool
to study the subcellular distribution of these two proteins, their
ability to interact with each other, and their individual contribution
to the biogenesis of caveolae. We show that caveolin-2 has a strikingly
different subcellular distribution than caveolin-1; the former protein
localizes to the Golgi complex, whereas the latter one is
preferentially found at the cell surface. In addition, we show that,
despite their different distributions, the two proteins interact with
each other and that furthermore caveolin-1 promotes redistribution of a
fraction of caveolin-2 to the cell surface, to detergent-insoluble
complexes, and to caveolae. Finally, we demonstrate that caveolin-2
does not share the capability of caveolin-1 to promote the formation of
plasmalemmal caveolae but may contribute to the formation of post Golgi
vesicles. Our data confirm and extend previous observations that
indicate that caveolae are assembled with a striking selectivity for
the basolateral surface of epithelial cells (16, 23).
 |
EXPERIMENTAL PROCEDURES |
Materials--
Cell culture reagents were purchased from Life
Technologies, Inc., and chemicals were from Sigma unless otherwise
specified. The caveolin-1 and myc-tagged caveolin-1
cDNAs were provided by R. G. W. Anderson (University of
Texas, Southwestern, Dallas, TX). Caveolin-2 cDNAs were provided by
Michael Lisanti (Albert Einstein College of Medicine, Bronx, NY).
Monoclonal (mAb 2297) and polyclonal antibodies to caveolin-1, a
monoclonal antibody to caveolin-2 (mAb 65) (10) and a monoclonal
antibody to
-adaptin were purchased from Transduction Laboratories
(Lexington, KY). The monoclonal 9E10 and polyclonal A-14 antibodies to
c-myc epitope were from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA). A polyclonal antibody to mannosidase II was provided
by Kelley Moremen (University of Georgia, Athens, GA). A rabbit
polyclonal antibody against the Golgi marker GOS-28 was provided by
Tomas Sollner (Memorial Sloan-Kettering Cancer Center). A rabbit
polyclonal antibody to TGN-38 was provided by G. Banting (University of
Bristol, Bristol, UK). The pAdlox plasmid, CRE8 cells and
5 virus
were provided by Steve Hardy (Somatix Therapy Corp., Alameda, CA). The
ECL Western blot detection kit was purchased from Amersham Pharmacia Biotech.
Cell Culture--
Cells were grown for 3-5 days at high density
either in Dulbecco's modified Eagle's medium (MDCK cells) or in
Ham's F-12/Coon's (Sigma) modified media (FRT cells) supplemented
with 5% fetal bovine serum. Cells were plated either on tissue culture
dishes, glass coverslips or polycarbonate Transwell R chambers (Corning Costar Corporation, Cambridge, MA).
Transfection with Caveolin cDNAs--
Full-length human
caveolin-1 cDNAs (untagged or myc-tagged), were
subcloned into either pcDNA3 (Invitrogen, San Diego, CA) or pCB7
vectors (15), which contained, a neomycin- or a hygromycin-selectable marker, respectively. Full-length as well as the
-isoform of human
untagged or myc-tagged caveolin-2 cDNAs were subcloned
into the pCB7 vector (9). Liposome-mediated transfection of MDCK or FRT
cells with LipofectAMINE was carried out according to manufacturer's instructions. Selection of transformants was performed in the presence
of 500 µg/ml geneticin or 200 µg/ml hygromycin. Individual clones
were obtained by limiting dilution.
Western Blot Analysis--
Cells were extracted for 60 min on
ice with Tris-buffered saline (25 mM Tris, pH 7.5, 0.15 M NaCl) containing 60 mM n-octyl
-D-glucopyranoside (24). After centrifugation at 13,000 rpm for 10 min in a tabletop microcentrifuge, the protein content of
the extracts was determined using a Bio-Rad DC protein assay kit with
bovine serum albumin as a standard. After SDS-polyacrylamide (15%) gel
electrophoresis and transfer to nitrocellulose (Schleicher & Schuell),
blots were probed with anti-caveolin-1 IgG (pAb 1/10,000 or mAb 2297, 1/1000), anti-caveolin-2 IgG (mAb 65, 1/250), or polyclonal
anti-myc IgG (1/5000). 20-50 µg of cell extract were routinely loaded per lane. The bound horseradish peroxidase-conjugated reporter IgG was detected on filters using the ECL system. Band intensities were quantified by densitometry with the NIH Image 1.60 package.
Immunofluorescence--
Cells were grown on coverslips or
polycarbonate Transwell R filters and cultured for 3-5 days after
confluency. Cells were then briefly washed three times with
phosphate-buffered saline, pH 7.4, containing 2.7 mM KCl,
0.5 mM CaCl2, and 0.5 mM
MgCl2 (PBS/CM) and fixed for 30 min in PBS/CM containing
2% formaldehyde (freshly prepared from paraformaldehyde) at 22 °C.
Cells were rinsed with PBS and treated with 25 mM
NH4Cl in PBS for 10 min to quench residual aldehyde groups.
Cells were then permeabilized with 0.075% saponin in PBS containing
0.2% bovine serum albumin (PBSSA) for 10 min. For immunolabeling, the
cells were then incubated with PBSSA containing one of the following
antibodies: (a) pAb anti-caveolin-1 (1:200) or
(b) pAb anti-myc-epytope (1:200), mAb 65 anti-caveolin-2 (1:100), anti-mannosidase II (1:500), anti-GOS-28 (1:500), anti-TGN38 (1:500), and anti-
-adaptin (1:400). Bound primary antibodies were visualized with the appropriate fluorescein isothiocyanate- or Texas Red-conjugated (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) secondary antibodies at a dilution
of 5 µg/ml. Incubations with primary and secondary antibodies were
for 3 and 1 h, respectively. Cells were washed five times with
PBSSA between incubations. Control experiments for the specificity of
the antibodies consisted in: (a) immunofluorescence staining for caveolin-1 of wild type FRT cells that express caveolin-2 but no
caveolin-1; (b) immunostaining of wild type MDCK cells, wild
type FRT cells, and FRT cells transfected with caveolin-1 with
anti-myc epitope antibodies; and (c)
immunostaining of cells in the absence of primary antibodies.
Coverslips and polycarbonate Transwell filters were mounted onto slides
with Vectashield (Vector Laboratories, Inc., Burlingame, CA) and
observed under Molecular Dynamics or Bio-Rad laser scanning confocal
fluorescence microscopes. Alternatively, fluorescence microscopy was
performed on a Nikon E-600 microscope using the following filter cubes
(Chroma Technologies, Barttleburo, VT): rhodamine (G-2E/C DM 565,)
Cy5 (HYQ, DM 66), fluorescein (B-2E/C DM 505); a UV filter cube
(EF-4ex390/em460 DC 420) was obtained from Nikon Corp. Images were
collected using a cooled charged coupled device camera (CCD 1000 PB,
Princeton Instruments) and were transferred to a computer workstation
running the metaMorph imaging software (Universal Imaging, West
Chester, PA).
Immunoelectron Microscopy on Ultrathin-frozen
Sections--
Cells grown on 6-well plastic Petri dishes were fixed
for 20 min in 4% paraformaldehyde/0.1% glutaraldehyde and were washed and stored in PBS containing 0.02% azide. They were cryoprotected in
2.3 M sucrose in PBS, scraped from the plates, and placed
on a cryostat support for freezing. Cells were sectioned at
110 °C
on a Reichert FC4D ultracryomicrotome (Leica Instruments, Deerfield, IL), and sections were collected on nickel grids. For immunostaining, the grids were blocked on a drop of PBS containing 1% bovine serum albumin/1% normal goat serum for 20 min. They were incubated with anti-caveolin-2 monoclonal antibody 65 diluted 1:300 (in commercial antibody diluent; DAKO Corp.) overnight at 4 °C. After rinsing three
times for 5 min each time in PBS, they were incubated with goat
anti-mouse IgG coupled to 10 nm of colloidal gold, diluted 1:25 in
antibody diluent, for 1 h at room temperature. After further rinsing three times for 5 min in PBS, the sections were fixed in 1%
glutaraldehyde for 10 min, rinsed in distilled water, and stained and
embedded using 2% methylcellulose containing 0.2% uranyl acetate for
10 min, on ice. Sections were examined and photographed using a Philips
CM10 electron microscope.
Preembedding Immunocytochemistry--
Cells grown on 6-well
clusters were fixed in 3% paraformaldehyde (10 min, 37 °C), scraped
from the wells, and exposed to 0.1% Triton X-100 for 5 min at room
temperature (25). They were then washed for 30 min in PBS containing
0.01 M glycine and 1% bovine serum albumin. For double
immunogold labeling, the cells were incubated overnight with mAb 65 to
caveolin-2 (1:100) and anti-caveolin-1 pAb (1:100) followed by 5 nm of
gold goat anti-rabbit IgG conjugate (1:50) and 10 nm gold-goat
anti-mouse IgG conjugate, (1:50) for 3 h. After washing, the cells
were fixed for 30 min in 1% glutaraldehyde in 0.1 M
cacodylate buffer, pH 7.4. The cells were then sedimented, postfixed in
1% OsO4, stained with 0.5% tannic acid (10 min), followed by staining
in block for 20 min in 1% uranyl acetate, dehydrated, and embedded in epon.
Post-embedding Immunostaining--
Cells grown on filters were
fixed in 4% paraformaldehyde for 30 min, dehydrated in cold solutions
of increasing ethanol concentrations, and then embedded in Unicryl
according to the protocol described by British BioCell International
(Cardiff, UK). Thin sections were collected on nickel grids, rehydrated
in PBS containing 1% bovine serum albumin and 10% normal goat serum
and then incubated with the mAb 65 to caveolin-2 followed by 5 or 10 nm
of gold goat anti-mouse IgG conjugate. The grids were then
counterstained with uranyl acetate and lead citrate.
Thin Section Electron Microscopy--
Cells grown on
polycarbonate TranswellR filters were processed for thin
section electron microscopy by standard procedures as described
previously (15). Thin sections were cut parallel to the plane of the
culture with a Sorvall MT 5000 microtome and stained with uranyl
acetate and lead citrate. Specimens were examined and photographed in a
JEOL 100 CXII electron microscope.
For quantitation of caveolae, the specimens were treated with 1%
tannic acid in 0.05 M cacodylate buffer for 30 min to
increase membrane contrast (2). To determine the number of caveolae in
cells expressing caveolin-1, about 30-40 cell segments from two
different experiments (15-20 fields/experiment) were randomly photographed. Quantitative evaluations were carried out on micrographs printed at the same magnification (×28,000). Quantitation was performed with an NIH Image 1.52 program.
Sucrose Gradient Ultracentrifugation--
The procedure used for
preparing low density Triton X-100 insoluble membranes (LDTIM) were
adapted from previously described protocols (24, 26). Cells grown to
confluency in 150-mm dishes (3.6 × 107 cells) were
rinsed with phosphate-buffered saline (150 mM NaCl, 20 mM sodium phosphate, pH 7.4) containing 0. 5 mM
MgCl2 and 0.5 mM CaCl2. Cells were
then scraped and lysed for 30 min at 4 °C in 2 ml of 1% Triton
X-100 in TNE buffer (150 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl, pH 7.4). Lysates were homogenized using eight strokes of a Dounce homogenizer, brought to 40% sucrose by adding 2 ml
of 80% sucrose in TNE without TX-100, and placed in an ultracentrifuge tube. The samples were then overlaid with a sucrose step gradient (5 ml
of 35%, 1 ml of 15%, and 1 ml of 5% in TNE buffer, and 1 ml of TNE
buffer). Gradients were centrifuged for 20 h at 4 °C at 34,000 rpm in a Beckman SW41 rotor. Twelve fractions of 1 ml were collected
starting from the top of the tube.
Velocity Gradient Centrifugation--
To estimate the oligomeric
state of caveolins in FRT and MDCK cells, we used a previously
described protocol (10) with minor modifications. Briefly, 500 µl of
samples prepared in 25 mM Mes, pH 6.5, 150 mM
NaCl buffer plus 60 mM n-octyl
-D-glucopyranoside were loaded atop a 5-50% linear
sucrose gradient (4.3 ml) and centrifuged at 40,000 rpm for 18 h
in a SW-50.1 rotor. Twelve gradient fractions were harvested from the
top, and aliquots were subjected to immunoblot analysis. Molecular mass
standards (Sigma) were as follows: carbonic anhydrase (29 kDa), bovine
serum albumin (66 kDa), alcohol dehydrogenase (150 kDa),
-amylase
(200 kDa), apoferritin (443 kDa), and thyroglobulin (670 kDa).
Construction of Adenovirus Vectors--
E1 deleted
replication-defective adenovirus vectors carrying caveolin-1 or
myc-caveolin-2 cDNAs were constructed by using CRE/Lox
assisted recombination according to previously described methods (27).
In brief, full-length caveolin-1 and full-length myc-caveolin-2
cDNAs were subcloned into pAdlox shuttle plasmid. Shuttle plasmids
were co-transfected along with purified
5 viral genomic DNA into
CRE8 cells (293 cells stably transfected with CRE recombinase). After 1 week of transfection the crude viral lysate was subjected to three or
four successive rounds of passage through CRE8 cells to increase the
percentage of recombinant viruses over that of
5. The percentage of
5 versus recombinant virus was determined by restriction
digest of viral DNA with the enzyme Bsa B1. The
5 virus itself is
E1-deficient and has been modified to contain two LoxP sites flanking
the packaging sequence. Although CRE8 cells complement the E1
deficiency, the
5 virus is selected against by CRE8 cells because
the viral genome tends to circularize after CRE-mediated excision of
the packaging sequence, which prevents insertion of the viral DNA into
nascent virus particles. Recombinant viruses were verified as
E1-deleted by polymerase chain reaction, and replication deficiency
ensured by passage through nonpermissive cell lines (MDCK and FRT
cells). A large preparation of viruses was then grown in CRE8 cells or
293 cells and titered (plaque forming units) on 293 cells.
Transduction with Adenovirus Vectors--
Transduction with
adenoviruses was performed on 3-5 days confluent cells. Cells were
rinsed in 10 mM HEPES buffered Dulbecco's modified
Eagle's medium containing 0.2% bovine serum albumin (transduction medium). For the immunofluorescence assays 200 µl of the appropriate vector diluted in transduction medium was added to the cells grown on
coverslips in 24-well tissue culture dishes. To determine the levels of
caveolins transduced by adenoviruses, cells grown in 6-well tissue
culture plates were infected with 400 µl of caveolin-1 or caveolin-2
adenovirus and then extracted for Western blot analysis as described
above. After 2 h postinfection at a multiplicity of infection of
20 plaque forming units/cell, the adenovirus-containing medium was
removed, the cells were rinsed once with Dulbecco's modified Eagle's
medium, and then the appropriate serum-containing medium was added.
Cells were analyzed 24 h post-infection.
 |
RESULTS |
Expression of Caveolin-1 and Caveolin-2 in FRT and MDCK
Cells--
To characterize the localization of caveolin-1 and
caveolin-2 in FRT and MDCK cells and the effect of caveolin-1
expression on caveolin-2 localization, we prepared stable clones
expressing either one or both of these proteins simultaneously (Fig.
1). In the FRT clones selected for study
the levels of expression of transfected caveolin-2 were three to five
times higher than the levels of endogenous caveolin-2. To distinguish
it from endogenous caveolin-2, transfected caveolin-2 had a
myc epitope; as shown below, possession of this
myc epitope did not affect the localization of the protein
or its ability to interact with caveolin-1. The levels of transfected
caveolin-1 expressed in FRT cells ranged from half to twice the levels
of endogenous caveolin-1 in MDCK cells.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
Expression of exogenous caveolins-1 and -2 in
MDCK and FRT cells. A-C, Western blots showing the
comparative expression of caveolin-1 and caveolin-2 in wild type
(WT) and transfected FRT cells (clones ML-5, ML-12, 18, BM1,
BM2, and D2) and in transfected MDCK cells (R2 and R10). 50 µg of
cell extract were loaded per lane for blots shown in A and
B, and 20 µg of cell extract were loaded for the blot
shown in C. mAb 65 was used for caveolin-2 (A),
pAb for caveolin-1 (B), and pAb A-14 to myc
epitope (C). Arrows mark the position of the
endogenous and the myc-tagged exogenous caveolin-2. Note
that the myc-tagged ( ) isoform of
caveolin-2 has a molecular mass close to that of the endogenous
caveolin-2. T1, FRT cells transfected with
myc-caveolin-1. T2, FRT cells transfected with
untagged caveolin-1. The expression of caveolin-1 in untransfected (WT)
and transfected FRT cells is compared with the endogenous expression in
MDCK cells. Molecular mass markers (top to
bottom) are 198, 113, 75, 49, 33, 24, 17, and 7 kDa.
|
|
Localization of Caveolin-1 and Caveolin-2 in MDCK and FRT
Cells--
The subcellular localization of caveolins-1 and -2 in FRT
and MDCK cell lines was studied by indirect immunofluorescence on a
confocal microscope or on a Nikon Eclipse fluorescence microscope linked to an image collection system (see "Experimental
Procedures"). Endogenous (rat) caveolin-2 detected in FRT cells by
immunostaining with a monoclonal antibody against human caveolin-2 (mAb
65) exhibited an almost exclusively juxtanuclear distribution (Fig.
2A, WT). FRT cell
lines overexpressing full-length myc-caveolin-2 displayed the same juxtanuclear caveolin-2 immunostaining as detected by a
polyclonal antibody against the myc epitope (Fig.
2B, ML-5), indicating that the epitope did not
interfere with the localization of the protein. The monoclonal antibody
65 against human caveolin-2 did not recognize the endogenous canine
caveolin-2 in MDCK cells either by immunofluorescence (not shown) or by
Western blot (Fig. 1A, WT), but transfection of
human caveolin-2 into MDCK cells, either the wild type
isoform
(Fig. 2G, pool) or the myc-tagged
isoform
(Fig. 2H, R10), resulted in a distinct
juxtanuclear signal by immunofluorescence and in a strong Western blot
signal (Fig. 1). The localization pattern of the truncated
isoform of caveolin-2 in stable transfectant clones or in uncloned cell populations was similar to that of the full-length
isoform (data not shown). Immunostaining of MDCK cells with a polyclonal caveolin-1 antibody revealed punctate fluorescence at the cell surface in accordance with previous reports (4, 28) (Fig. 2I). In xz confocal sections, caveolin-1 was detected on both apical and basolateral membranes and to a much lesser extent in intracellular vesicular structures, and very little staining, if any, was detected at
the level of the Golgi complex (Fig. 2J). An overall similar apical and basolateral distribution of transfected caveolin-1 was
observed in FRT cells (Fig. 2C, Cav-1,
T2). As is the case for caveolin-2, the myc tag
did not affect the localization pattern of caveolin-1 (Fig.
2D, Cav-1, T1).

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 2.
Differential localization of caveolin-1 and
caveolin-2 in MDCK and FRT cells. Confluent monolayers of MDCK or
FRT cell lines grown on polycarbonate filters expressing various
combinations of endogenous and exogenous caveolin-2 and caveolin-1 were
analyzed by immunofluorescence and laser scanning confocal microscopy.
Note the predominantly juxtanuclear localization of the endogenous
caveolin-2 in wild type FRT cells (A) as well as of the
myc-tagged overexpressed caveolin-2 in FRT stable
transfectants (B). A similar juxtanuclear distribution of
caveolin-2 was detected in MDCK cells after transfection with wild type
full-length caveolin-2 cDNA (G) or of
myc-tagged caveolin-2 (H). In contrast,
transfected wild type and myc-tagged caveolin-1 displays a
punctate and mainly surface localization in FRT cells (C-F)
identical to that displayed by endogenous caveolin-1 in MDCK cells
(I and J). In xz confocal sections, caveolin-1 is
seen equally distributed on the apical and basolateral membranes in FRT
cells (E and F) and in MDCK cells (J).
Arrow in C and J point at small
intracellular vesicular compartments positively stained for caveolin-1.
Bars, 5 µM.
|
|
Caveolin-2 Co-localizes with Golgi Cisternae and TGN Markers in
MDCK and FRT Cells--
Double-labeling immunofluorescence experiments
with antibodies against Golgi markers (mannosidase II and GOS-28) or
TGN markers (TGN-38) demonstrated an overlapping distribution of
caveolin-2 with these markers in FRT cells (Fig.
3, A-F). Caveolin-2 partially co-localized with
-adaptin in MDCK (Fig. 3, G and
H) cells. Immunogold localization on ultracryosections
revealed caveolin-2 on tubulovesicular structures in the Golgi area
(Fig. 4).

View larger version (61K):
[in this window]
[in a new window]
|
Fig. 3.
Double-immunofluorescence of caveolin-2 with
Golgi or TGN markers in FRT and MDCK cells. In wild type FRT cells
(A-F) there is a partial overlapping staining of caveolin-2
(A, C, and E) with mannosidase II
(A and B), with GOS-28 (C and
D), and with TGN 38 (E and F). In MDCK
cells (G and H) a partial overlapping
distribution of caveolin-2 with adaptin is observed.
Bars, 5 µM.
|
|

View larger version (135K):
[in this window]
[in a new window]
|
Fig. 4.
Localization of caveolin-2 in the Golgi
region of FRT cells. Ultrathin cryosections of FRT cells
overexpressing caveolin-2 (clone ML-12) were stained by immunogold. The
gold labeling is restricted to numerous vesicles and tubules in the
Golgi region of the cell. Little or no label can be detected over
cellular compartments, demonstrating the specificity of the labeling.
G, Golgi complex; M, mitochondria.
Bar, 0.1 µM.
|
|
Expression of Caveolin-1 in FRT Cells Promotes Recruitment of
Caveolin-2 at the Plasma Membrane--
In MDCK cells, caveolin-2 was
detected not only at the Golgi complex, but also, albeit in smaller
amounts, at the plasma membrane (Fig. 2, G and
H). This was observed for transfected human caveolin-2 both
with and without a C-terminal myc tag (Fig. 2, G
and H). In contrast, we did not detect any plasma membrane
staining for endogenous caveolin-2 either in wild type FRT cells or in
FRT cells overexpressing caveolin-2 tagged with myc epitope
(three to four times higher levels than the endogenous caveolin-2)
(Fig. 2, A and B, and Fig.
5, A, C, and
E). These results suggested that the simultaneous expression
of both caveolin-1 and caveolin-2 might promote the recruitment of
caveolin-2 at the plasma membrane. To test this hypothesis, we
generated double transfectant FRT cell lines expressing caveolin-1 and
caveolin-2. In these clones the immunostaining of caveolin-2 resembled
that seen in MDCK cells: mainly Golgi complex but with a definite
labeling of the plasma membrane (Fig. 5, B, D,
and F). Interestingly, the same observation was true for
both the
isoform (Fig. 5, BM1 and BM2) and
for the shorter
isoform (Fig. 5, D2).

View larger version (106K):
[in this window]
[in a new window]
|
Fig. 5.
Caveolin-2 is recruited to the plasma
membrane in the presence of caveolin-1. Caveolin-2 is confined to
the Golgi area of confluent monolayers of FRT cells overexpressing
caveolin-2, isoform (A and C) or isoform
(E) but redistributes partially to the plasma membrane in
FRT cell lines co-expressing transfected caveolin-1 (B,
D, and F). Caveolin-2 expression was detected
with pAb A-14 that recognizes the myc epitope. Control
experiments confirmed the specificity of the antibody for the
myc epitope. The levels of expression of caveolin-1 and
caveolin-2 in the cell lines shown in this figure can be found in the
Western blots of Fig. 1. Bars, 5 µM.
|
|
To confirm that caveolin-1 was required for the recruitment of
caveolin-2 to the plasma membrane and to completely eliminate the
possibility that this observation might be due to clonal variation or
to the saturation of the intracellular machinery responsible for the
Golgi retention of caveolin-2, we carried out additional experiments
using an adenovirus-mediated gene transfer approach. For these
experiments, FRT cell lines expressing both transfected and endogenous
caveolin-2 were transduced with adenoviruses carrying the
subunit
of caveolin-1 (Adcav-1) and, in control experiments, with adenoviruses
carrying caveolin-2 (Adcav-2). Fig. 6
shows that transduction of FRT cells with Adcav-1 or Adcav-2 resulted in the expression of high levels of caveolin-1 or caveolin-2, respectively, as detected by Western blot. Control immunofluorescence experiments demonstrated that treatment of ML-5, ML-12 and 18/FRT clones (Fig. 7, A,
D, and G) with Adcav-2 did not affect the
juxtanuclear localization of caveolin-2 (Fig. 7, B,
E, and H), indicating that the higher levels of
expression of the protein did not modify its stringent localization to
the Golgi complex. In contrast, transduction of caveolin-1 into ML-5,
ML-12/FRT sublines, resulted in a redistribution of a fraction of
caveolin-2 to the cell surface (Fig. 7, C and F).
A similar observation was made for an FRT cell line overexpressing the
short (
) subunit of caveolin-2: transduction of caveolin-1 caused a
considerable redistribution of this protein to the cell surface (Fig.
7I, 18).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 6.
Adenovirus-mediated expression of caveolin-1
and caveolin-2 in FRT cells. Confluent FRT monolayers were
transduced with adenoviruses encoding caveolin-1 (Adcav-1) or
caveolin-2 (Adcav-2). Lysates were analyzed by SDS-polyacrylamide gel
electrophoresis (20 µg/lane), and the caveolins were detected by
Western blot with monoclonal antibody 2297 to caveolin-1 (top
panel) or with monoclonal antibody 65 against caveolin-2
(bottom panel). Arrows mark the positions of the
myc-tagged isoform (top), endogenous
caveolin-2 (middle), and isoform
(bottom).
|
|

View larger version (135K):
[in this window]
[in a new window]
|
Fig. 7.
Expression of caveolin-1 via adenoviruses
redistributes caveolin-2 to the plasma membrane. FRT cell lines
overexpressing full-length caveolin-2 (clones ML-5 and ML-12) or the
isoform of caveolin-2 (clone 18) but lacking caveolin-1 were
transduced with Adcav-2 (B, E, and H)
or Adcav-1 (C, F, and I), and the
localization of caveolin-2 was analyzed by immunofluorescence 24 h
later. In the absence of caveolin-1 (A, D, and
G) or upon adenovirus mediated transduction of caveolin-2
(B, E, and H), the localization of
caveolin-2 is at the Golgi complex. However, upon transduction of
caveolin-1, caveolin-2 is also seen at the plasma membrane
(C, F, and I). Immunofluorescence
staining for caveolin-2 was performed with pAb A-14 that recognizes the
myc epitope. Bars, 2.5 µM.
|
|
Analysis of double immunofluorescence experiments indicated a clear
co-localization of caveolin-1 and caveolin-2 in plasma membrane patches
(Fig. 8, D and E,
arrows). Immunogold electron microscopy demonstrated the
co-distribution of both caveolins in plasma membrane patches and on
plasmalemmal caveolae (Fig. 8).

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 8.
Caveolin-2 is recruited to caveolae in the
presence of caveolin-1. A-C, post-embedding immunogold
staining of caveolin-2. In FRT cells expressing exogenous caveolin-1
(clone BM1), immunogold detects caveolin-2 (arrows) both on
the apical (A) and basal membrane (B). Note that
the concentration of caveolin-2 is higher on the basolateral membrane
(B) where is present in flat patches (B) or on
caveolae (C, arrows). Bars, 0.05 µM. D and E, double
immunofluorescence analysis of FRT cells transfected with caveolin-1
(clone T2) using a caveolin-2 mAb (D) and a caveolin-1 pAb
(E) show that the two caveolins co-patch at the plasma membrane
(arrows) and in perinuclear regions (arrowheads).
Bars, 5 µM. Control experiments confirmed the
specificity of these antibody probes; no cross-reaction was observed.
F-H, pre-embedding immunogold staining for caveolin-1 and
caveolin-2. The two caveolins (10 nm of gold for caveolin-2; 5 nm of
gold for caveolin-1) colocalize on caveolae (F) and on
cytoplasmic vesicles apparently not connected to plasmalemma
(G) and are also seen in the same plasmalemmal noncaveolar
domains (H) (arrowheads, caveolin-2;
arrows, caveolin-1). Bars, 0.05 µM.
|
|
Expression of Caveolin-1 in FRT Cells Promotes Recruitment of
Caveolin-2 to the Low Density Triton-insoluble Membrane
Fraction--
The partial change in distribution of caveolin-2 in the
presence of caveolin-1 and the codistribution of caveolin-1 and
caveolin-2 in the plasma membrane suggested that the two proteins
interact in vivo. Previous work has shown that a fraction of
both proteins co-immunoprecipitates in MDCK cells and gets incorporated
in detergent insoluble complexes (8). However, it is not clear whether
both proteins share the ability to incorporate into detergent-insoluble clusters (rafts) or only one of them has this ability and the other one
follows. To study this important point, we analyzed the floatation
characteristics of caveolin-2 in the presence or in the absence of
caveolin-1. We initially compared the floatation of caveolin-2 in FRT
and MDCK cells solubilized with Triton X-100 at low temperature (24).
To separate LDTIM from the Triton X-100 soluble material, we placed the
Triton extract, made 40% in sucrose concentration, under 0-35%
sucrose density gradients. After overnight centrifugation, aliquots
from the different fractions were subjected to immunoblot analysis
using caveolin-1 or caveolin-2 specific antibodies. Fig.
9 shows that, in FRT cells, endogenous
(Fig. 9A, WT) and overexpressed (Fig.
9A, myc-cav2) caveolin-2 is found at the bottom
of the sucrose gradient (fractions 9-12), indicating that this protein
lacks intrinsic capability to associate with LDTIM. In contrast, the
transfection of caveolin-1 into FRT cells (Fig. 9A,
panel b) or the presence of endogenous caveolin-1 in MDCK
cells (Fig. 9A, panel c) results in the
association of a substantial fraction of caveolin-2 with LDTIM
(fractions 3-5 in sucrose density gradient). A large fraction of
caveolin-1 was found in association with LDTIM in MDCK and in FRT cells
(Fig. 9B). These results indicate that the simultaneous
expression of caveolin-1 and caveolin-2 is required for the
incorporation of caveolin-2 into rafts. On the other hand, because we
do not have a cell line in which caveolin-1 is expressed in the absence
of caveolin-2, our data do not allow us to conclude that caveolin-1 can
associate with rafts independently of caveolin-2.

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 9.
Expression of caveolin-1 in FRT cells causes
recruitment of caveolin-2 to the Triton insoluble low density membrane
fraction. A, floatation of caveolin-2 in the absence or
presence of caveolin-1. Confluent monolayers of FRT and MDCK cell lines
were extracted with Triton X-100 at 4 °C (see "Experimental
Procedures"). The cell extract was made 40% in sucrose concentration
and loaded under a 0-35% sucrose density gradient. After
centrifugation for approximately 20 h, fractions were collected
and analyzed by immunoblot (mAb 2297 for caveolin-1 and mAb 65 for
caveolin-2). In wild type FRT cells (A, panel a)
most of caveolin-2 was detected in the bottom fractions (9-12)
corresponding to the Triton-soluble material. In contrast, in FRT cells
expressing transfected caveolin-1 (A, panel b) as
well as in MDCK cells (A, panel c) a large
fraction of caveolin-2 was also found in the top fractions (3-5),
corresponding to the low density regions of the gradient. In
B, the floatation pattern of caveolin-1 in FRT and MDCK
cells is shown for comparison. B, velocity gradient analysis
of the oligomeric state of caveolin-2 in the absence or presence of
caveolin-1. FRT and MDCK cells were extracted (see
"Experimental Procedures"), loaded atop a 5-50% sucrose density
gradient and centrifuged for 18 h. The arrows mark the
positions of molecular mass standards. The distribution of caveolin-2
and caveolin-1 in the 12 gradient fractions collected was detected by
immunoblot analysis using the mAb 65 for caveolin-2 and the mAb 2297 for caveolin-1. Note that in WT/FRT cells (C, panel
a) that lack caveolin-1 expression, a significant fraction of
caveolin-2 was present in fractions 4-8, corresponding to approximate
apparent molecular masses of 66-443. The distribution of transfected
overexpressed myc-caveolin-2 in ML-12/FRT cells was
virtually identical to that of endogenous caveolin-2. Note that in
ML-12/FRT cells 2 bands are visible, The lower band corresponds to the
endogenous caveolin-2, and the upper one corresponds to the full-length
exogeneous myc-tagged caveolin-2. Overexpression of
caveolin-2 as well as the myc epitope did not affect the
size of caveolin-2 oligomers. In FRT cells (C, panel
b) that co-express caveolin-1 (T2/FRT cells), caveolin-2 sediments
with a higher apparent molecular mass (fractions 6-10, corresponding
to 200-669 kDa), which is also the apparent molecular mass of
caveolin-1 (D) under the same conditions.
|
|
Finally, velocity gradients were performed to study the formation of
caveolin-1 and caveolin-2 oligomers (Fig. 9C). In these gradients, caveolin-2 from FRT cells not expressing caveolin-1 was
present in fractions 4-8, corresponding to an estimated molecular mass
of 66-443 kDa. In contrast, simultaneous expression of caveolin-1 resulted in an increased sedimentability of caveolin-2 to fractions 6-10 in the velocity gradient, corresponding to an estimated molecular mass of 200-669 kDa. Importantly, in MDCK cells, caveolin-2 also had a
high apparent molecular mass and was detected in fractions 6-10.
Parallel experiments demonstrated that in both MDCK and FRT cells,
caveolin-1 sedimented into fractions 6-10 (Fig. 9D). These
experiments demonstrate that expression of caveolin-1 promoted the
formation of caveolin-2 oligomers larger than those formed in the
absence of caveolin-1.
Formation of Basolateral Plasma Membrane Caveolae Is Induced by
Caveolin-1 but Not by Caveolin-2--
Ultrastructural examination
revealed an abundance and polarized distribution of plasmalemmal
caveolae in MDCK cells (Fig. 10). On
the apical membrane mainly coated vesicles were observed; caveolae were
very rarely seen (Fig. 10A). Some of the coated vesicles had
the same size as the infrequent apical caveolae (Fig. 10D) and exhibited fine cytoplasmic striations (Fig. 10E,
v1) morphologically distinct from the "classical"
clathrin coat (Fig. 10, v2). In contrast, on the basolateral
plasmalemma, caveolar profiles, highlighted by tannic acid (see
"Experimental Procedures"), were more abundant than coated vesicle
profiles (Fig. 10B). Some basolateral caveolae were seen
near the cell surface apparently not connected to the plasma membrane
(Fig. 10C), others had open stomata or displayed a
characteristic straight trilaminar fusion membrane at the contact with
the plasmalemma (Fig. 10F).

View larger version (114K):
[in this window]
[in a new window]
|
Fig. 10.
Caveolin-1, but not caveolin-2,
promotes the formation of basolateral caveolae in FRT cells.
Confluent monolayers of MDCK or FRT cells were processed for
transmission electron microscopy as described under "Experimental
Procedures." For all MDCK panels (A-F) and FRT panels
(G-L), the abbreviations are as follows: Ap,
apical plasmalemma; Bl, basolateral plasmalemma;
v and arrowheads, coated vesicles; c
and arrows, plasmalemmal caveolae. Specimens shown in
A-E and in G and H and in
K-L were additionally treated with 1% tannic acid.
A F, basolateral caveolae in MDCK cells. In MDCK cells,
which express both caveolin-1 and caveolin-2, caveolar structures
(arrow) are rare on the apical plasma membrane, whereas
coated vesicles (arrowheads) are frequent (A). In
contrast, on the basolateral membrane (B) plasmalemmal
caveolae (arrows) are very abundant. Note the absence of
tannic acid staining for the caveolar structure (arrow)
shown in C. D and E show higher
magnification of the apical vesicles. The caveolar structure in
D is apparently fused to the apical plasmalemma. The two
apical coated vesicles in E (V1 and
V2) have different sizes and appear to be decorated
by distinct coats. F illustrates basolateral plasmalemmal
caveolae with different morphological appearances: vesicles with
long-neck (C1), with open stoma
(C2), and with fused straight diaphragm
(C3). Transfection of caveolin-1 into FRT cells
promotes the formation of basolateral caveolae (G-J). On
the apical (Ap) plasmalemma mainly coated pits and vesicles
(arrowheads) are seen (G). The plasmalemmal
caveolae (arrows) are predominantly found on the basolateral
(Bl) membrane (H). Structural variation of
plasmalemmal caveolae induced by expression of caveolin-1 in FRT cells
(I and J). The apical caveolae had the following
distinctive morphology: vesicles with a straight fusion membrane
(I, 1), caveolae displaying a well-defined
single-layered stomatal diaphragm (I, 2), and
flask-shaped caveolae with elongated and narrow neck and sharply bent
rims (I, 3), apparently in apposition with an
intracellular vesicle (v) or caveolae fused in a tubular
structure (I, 4-6). The typical caveolar
structures found on the basolateral plasmalemma were: vesicles with
five-layered (J, 1) or three-layered (J, 2) diaphragms or caveolae
with open stomata (J, 3) or an elongated neck
(J, 4). Note the sharp angular edges at the bent
rims of caveolae (J, 1-4). Overexpression of
full-length caveolin-2 (K and L) in FRT cells
does not promote the morphogenesis of plasmalemmal caveolae. Note the
absence of caveolar profiles both on apical (Ap) and
basolateral (Bl) plasmalemmal membrane domains. The
appearance of the membrane is exactly the same as in wild type FRT
cells. Bars indicate 0.5 µM (A),
0.1 µM (B-F), 0.25 µM
(G, H, K, and L), or 0.05 µM (I and J).
|
|
Unlike MDCK cells, FRT cells do not have plasmalemmal caveolae (15) and
lack both caveolin-1 protein and mRNA (21, 22). Fig. 10
(G and H) shows that expression of caveolin-1 in
FRT cells induces the morphogenesis of plasmalemmal caveolae with the
same predominantly basolateral distribution as described for MDCK
cells. Coated pits/vesicles are practically the only vesicle type
observed on the apical plasmalemma (Fig. 10G), whereas both
caveolae and coated pits/vesicles are found on the basolateral plasma
membrane (Fig. 10H). The surface distributions of caveolae
and coated pits/vesicles were quantified and are presented in Table
I. Caveolae were vastly more frequent on
basolateral membranes than on apical membranes, by a factor of over
99.3:1-99.5:1 in FRT cells and 99.7:1 in MDCK cells. In contrast,
coated vesicles were almost evenly distributed on apical and
basolateral surfaces in both cell lines.
View this table:
[in this window]
[in a new window]
|
Table I
Quantitative analysis of caveolar profiles per unit length (mm) of
membrane in MDCK cells and in wild type and FRT cells expressing
exogeneous caveolin-1
|
|
Fig. 10 (I and J) shows the structure of
plasmalemmal caveolae induced by the expression of caveolin-1 in FRT
cells. Most caveolae had either on open stoma or an elongated neck with
a sharply angled contact with the plasmalemma. Some caveolae exhibited
distinctive neck diaphragms, which may represent intermediate stages in
the fusion to or fission from the plasma membrane.
As demonstrated by the quantitative data in Table I, wild type FRT
cells that express low levels of caveolin-2 but not caveolin-1 displayed practically no plasmalemmal caveolae. Overexpression of
caveolin-2 in FRT cells after transfection of full-length
myc-caveolin-2 resulted in an approximately 4-fold increase
in the total level (endogenous plus exogenous) of this protein (Fig.
1). Nonetheless, the electron microscopy experiments indicated that
overexpression of caveolin-2 (full-length or
isoform) in FRT cells
did not induce the assembly of plasmalemmal caveolae (Fig. 10,
K and L).
 |
DISCUSSION |
The functional significance of the existence of various caveolin
types is not understood. Because caveolin-1 and caveolin-2 are
expressed in similar tissues and the expression of both is increased
simultaneously upon differentiation of adipocytes (9), it is likely
that they may have either redundant or complementary functions. In this
report, we took advantage of the availability of the FRT cell line,
which expresses no caveolin-1 and low levels of caveolin-2, to study
the effects of caveolin-1 expression on the subcellular localization
and biochemical properties (oligomerization, association with
rafts) of caveolin-2.
We show that, in confluent FRT cells, caveolin-2, either endogenous or
overexpressed by transfection or adenovirus transduction of its
cDNA, has a predominant localization at a juxtanuclear compartment
that is co-labeled with markers of the Golgi cisternae (Man II, GOS-28)
and the TGN (TGN-38). A similar localization of caveolin-2 was observed
in polarized MDCK cells; for these experiments we used
myc-tagged caveolin-2, because our caveolin-2 antibody
recognized human and rat caveolin-2 but not canine caveolin-2. Control
experiments showed that myc-tagged caveolin-2 had an
identical localization as endogenous and overexpressed wild type
caveolin-2 in FRT cells. In contrast to caveolin-2, caveolin-1 had a
predominant plasma membrane localization in both polarized FRT and MDCK
cells. Importantly, a substantial fraction of caveolin-2 changed its distribution from the Golgi complex to the plasma membrane in the
presence of caveolin-1, in agreement with previous data that demonstrate an interaction of the two caveolins (8, 10, 29). This
differential localization of caveolins -1 and -2 was striking because
it was recently shown that in a nonpolarized fibroblastic cell line
(3T3-L1 cells), epitope-tagged caveolin-2 and endogenous caveolin-2 are
strictly co-localized with endogenous caveolin-1, both intracellularly
and at the level of the plasma membrane (9, 10). This suggests that the
differential localization of caveolins-1 and -2 may be at least in part
the result of the polarized epithelial cell phenotype. Indeed,
experiments with subconfluent MDCK and FRT cells detected a large
component of intracellular caveolin-1 in a juxtanuclear localization
(data not shown). Because it is now known that caveolin-1 and caveolae
are dynamic structures that can be internalized under certain
conditions (30, 31), the different localization of caveolins in
polarized cells may reflect different recycling patterns of the
proteins or their preferential utilization for different purposes,
e.g. new membrane synthesis and post-Golgi transport in
growing subconfluent cells and plasma membrane signaling processes in
quiescent confluent cells.
Because in both MDCK and FRT cells, the distribution of both caveolins
appears to overlap at the level of the intracellular compartment, we
speculate that they may cooperate specifically to carry out an
intracellular function, perhaps protein sorting in the TGN. Perhaps a
specific function of the caveolin-2 is to help in the formation of
large oligomers, which may be essential for a sorting function.
Oligomerization of caveolin is best understood for caveolin-1 and
occurs in two steps; in the first step the protein forms oligomers of
about 200 kDa in the endoplasmic reticulum, and in the second step,
which occurs later, probably in the Golgi apparatus, it forms very
large oligomers (> 600 kDa) that are detergent insoluble (18, 20). The
ability to form smaller oligomers depends on sequences in the
N-terminal domain, whereas the ability to form very large oligomers
depends on the palmitoylation of cysteine residues in the C-terminal
domain. Our data show that, when expressed singly, caveolin-2 sediments
in a velocity gradient with an apparent molecular mass of 66-450 kDa,
indicating that it can form homo-oligomers of up to ~24 molecules.
However, in the presence of caveolin-1, caveolin-2 sediments with an
apparent molecular mass of 200-660 kDa (oligomers up to ~36
molecules), indicating that the interaction of the two proteins
promotes both more efficient oligomerization and the formation of
larger oligomers. In part, this may be due to a differential ability to
bind to cholesterol. In contrast to caveolin-1, which binds cholesterol and associates with LDTIM or rafts (see Introduction), caveolin-2 does
not associate with LDTIM unless caveolin-1 is also expressed (Fig. 9).
These experiments suggest that caveolin-2 lacks the intrinsic ability
to bind cholesterol or LDTIM and that its association with rafts may
depend on its interaction with caveolin-1. The regulation of the
association with caveolin-1 may have important functional consequences,
because Scheiffele et al. (8) have presented data suggesting
that large homo-oligomers of caveolin-1 are involved in apical sorting
whereas hetero-oligomers of caveolin-1 and caveolin-2 might be involved
in basolateral sorting.
Another important difference between caveolin-1 and caveolin-2
highlighted by the experiments in this report appears to lie in their
ability to promote the formation of caveolae. FRT cells lacking
caveolin-1 have no caveolae (15, 22). Previous work has shown that
transfection of caveolin-1 into FRT cells promotes the assembly of
typical plasmalemmal caveolae (15), in agreement with results in other
cell lines from other laboratories (see the Introduction). The results
presented here demonstrate that overexpression of caveolin-2 in FRT
cells does not have the same effect; no plasmalemmal caveolae are
formed (Fig. 10). Quantitation of caveolae in both MDCK cells and FRT
cells indicates that the numbers of caveolae promoted by caveolin-1 in
FRT cells are roughly similar to the number of caveolae found
constitutively in MDCK cells. Intriguingly, these results are different
from those recently reported by Vogel et al. (16) for Caco-2
cells, which also lack caveolae and caveolin-1. In intestinal Caco-2
cells, transfection of caveolin-1 promotes assembly of caveolae, but
the levels observed are vastly different from those in MDCK cells.
Because Caco-2 cells lack caveolin-2, these data, taken together with
the data in this report, suggest that an association between caveolin-1 and caveolin-2 may promote a more efficient assembly of caveolae. Alternatively, Caco-2 cells may lack an additional component that facilitates assembly of caveolae. Intriguingly, although it appears to
localize at both apical and basolateral surfaces, caveolin-1 promotes
the formation of typical caveolae almost exclusively at the basolateral
plasma membrane of FRT cells. This is the same localization observed in
MDCK cells (Ref. 16 and this work) and in transfected Caco-2 cells. One
possible explanation of this observation may be that the critical
concentration of caveolin-1 needed for formation of caveolae is only
reached at the basolateral surface. Alternatively, if caveolin-1/2
hetero-oligomers are indeed preferentially targeted basolaterally (8),
this may provide additional support for a requirement for both
caveolins in the formation of caveolae. Polarized caveolar formation
may also reflect the different lipid composition of apical and
basolateral membranes (32). The very high concentration of
glycosphingolipids and cholesterol at the apical surface may result in
a very rigid membrane that cannot be easily folded into invaginated
caveolae. On the other hand, basolateral membranes may allow patches of
GSL/cholesterol to be folded into caveolae with the more flexible
phospholipids acting as hinges. Additionally, differences in the
submembrane cytoskeleton present in apical and basolateral membranes
(33) may restrict differentially the formation of apical caveolae. Finally, apical membranes may lack a caveolar component essential for
the formation of caveolae. The known functional properties of caveolins
and their fascinating variations in subcellular distribution guarantee
that further exploration will result in novel roles in intracellular
trafficking and polarized protein and lipid sorting.
 |
ACKNOWLEDGEMENTS |
We gratefully acknowledge Lee Cohen-Gould and
Peg McLaughlin for the expert assistance with electron microscopy.
 |
FOOTNOTES |
*
This work was supported by R01 Grants GM41771 and GM34107
from the National Institutes of Health and by a Jules and Doris Stein
Professorship from the Research to Prevent Blindness Foundation (to
E. R.-B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Supported by a grant from Pfizer Corp., a pilot grant from the
Einstein Diabetes Research and Training Center, and a research grant
from the American Diabetes Association.

Supported by NCI, National Institutes of Health Grant
R01-CA-80250 and grants from the Charles E. Culpeper Foundation, the G. Hardd and Leila Y. Mathers Charitable Foundation, and the Sidney Kimmel
Foundation for Cancer Research.
§§
To whom correspondence should be addressed: Weill Medical College
of Cornell University, Dyson Vision Research Institute-LC300, 1300 York
Ave., New York, NY 10021. Fax: 212-746-8101; E-mail: boulan@mail.med.cornell.edu.
 |
ABBREVIATIONS |
The abbreviations used are:
MDCK, Madin-Darby
canine kidney;
CHAPS, 3[(3-cholamidopropyldimethyl-ammonio]-2-hydroxypropanesulfonate;
FRT, Fischer rat thyroid;
LDTIM, low density Triton-insoluble membranes;
mAb, monoclonal antibody;
pAb, polyclonal antibody;
PBS, phosphate-buffered saline, pH 7.4;
TGN, trans-Golgi network;
Mes, 4-morpholineethanesulfonic acid.
 |
REFERENCES |
| 1.
|
Palade, G.
(1953)
J. Appl. Physiol.
24,
1424
|
| 2.
|
Simionescu, N.,
and Simionescu, M.
(1976)
J. Cell Biol.
70,
608-621[Abstract/Free Full Text]
|
| 3.
|
Schnitzer, J. E.,
Oh, P.,
Pinney, E.,
and Allard, J.
(1994)
J. Cell Biol.
127,
1217-1232[Abstract/Free Full Text]
|
| 4.
|
Rothberg, K. G.,
Heuser, J. E.,
Donzell, W. C.,
Ying, Y.-S.,
Glenney, J. R.,
and Anderson, R. G. W.
(1992)
Cell
68,
673-682[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Palade, G. E.,
and Burns, R. R.
(1968)
J. Cell Biol.
37,
633-649
|
| 6.
|
Kurzchalia, T. V.,
Dupree, P.,
Parton, R. G.,
Kellner, R.,
Virta, H.,
Lehnert, M.,
and Simons, K.
(1992)
J. Cell Biol.
118,
1003-1014[Abstract/Free Full Text]
|
| 7.
|
Okamoto, T.,
Schlegel, A.,
Scherer, P.,
and Lisanti, M.
(1998)
J. Biol. Chem.
273,
5419-5422[Free Full Text]
|
| 8.
|
Scheiffele, P.,
Vekade, P.,
Fra, A. M.,
Virta, H.,
Simmons, K.,
and Ikonen, E.
(1998)
J. Cell Biol.
140,
795-806[Abstract/Free Full Text]
|
| 9.
|
Scherer, P. E.,
Okamoto, T.,
Chun, M., I., N.,
Sodisn, H. F.,
and Lisanti, M. P.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
131-135[Abstract/Free Full Text]
|
| 10.
|
Scherer, P.,
Lewis, R.,
Volonte, D.,
Engelman, J.,
Galbiati, F.,
Couet, J.,
Kohtz, D.,
van Donselaar, E.,
Peters, P.,
and Lisanti, M.
(1997)
J. Biol. Chem.
272,
29337-29346[Abstract/Free Full Text]
|
| 11.
|
Parton, R. G.,
Joggerst, B.,
and Simons, K.
(1996)
Curr. Opin. Cell Biol.
8,
542-548[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Tang, Z.,
Scherer, P. E.,
Okamoto, T.,
Song, K.,
Chu, C.,
Kohtz, D. S.,
Nishimoto, I.,
Lodish, H. F.,
and Lisanti, M. P.
(1996)
J. Biol. Chem.
4,
2255-2261
|
| 13.
|
Fra, A. M.,
Williamson, E.,
Simons, K.,
and Parton, R. G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8655-8659[Abstract/Free Full Text]
|
| 14.
|
Li, S.,
Seitz, R.,
and Lisanti, M. P.
(1996)
J. Biol. Chem.
271,
3863-3868[Abstract/Free Full Text]
|
| 15.
|
Lipardi, C.,
Mora, R.,
Colomer, V.,
Paladino, S.,
Nitsch, L.,
Rodriguez-Boulan, E.,
and Zurzolo, C.
(1998)
J. Cell Biol.
140,
617-626[Abstract/Free Full Text]
|
| 16.
|
Vogel, U.,
Sandvig, K.,
and van Deurs, B.
(1998)
J. Cell Sci.
111,
825-832[Abstract]
|
| 17.
|
Monier, S.,
Parton, R.,
Vogel, F.,
Behlke, J.,
Henske, A.,
and Kurzchalia, T.
(1995)
Mol. Biol. Cell
6,
911-927[Abstract]
|
| 18.
|
Sargiacomo, M.,
Scherer, P. E.,
Tang, Z.,
Kuebler, E.,
Song, K. S.,
Sanders, M.,
and Lisanti, M. P.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
9407-9411[Abstract/Free Full Text]
|
| 19.
|
Murata, M.,
Peranen, J.,
Schreiner, R.,
Wieland, F.,
Kurzchalia, T. V.,
and Simons, K.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
10339-10343[Abstract/Free Full Text]
|
| 20.
|
Monier, S.,
Dietzen, D. J.,
Hastings, W. R.,
Lublin, D. M.,
and Kurzchalia, T. V.
(1996)
FEBS Lett.
388,
143-149[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Sargiacomo, M.,
Sudol, M.,
Tang, Z.,
and Lisanti, M.
(1993)
J. Cell Biol.
122,
789-807[Abstract/Free Full Text]
|
| 22.
|
Zurzolo, C.,
van't Hof, W.,
van Meer, G.,
and Rodriguez-Boulan, E.
(1994)
EMBO J.
13,
42-53[Medline]
[Order article via Infotrieve]
|
| 23.
|
Breton, S.,
Lisanti, M. P.,
Tyszkowski, R.,
McLaughlin, M,
and Brown, D.
(1998)
J. Histochem. Cytochem.
46,
205-214[Abstract/Free Full Text]
|
| 24.
|
Brown, D. A.,
and Rose, J. K.
(1992)
Cell
68,
533-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Moldovan, N. I.,
Heltianu, C.,
Simionescu, N.,
and Simionescu, M.
(1995)
Exp. Cell Res.
219,
309-313[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Abrami, L.,
Fivaz, M.,
Glauser, P.-E.,
Parton, R. G.,
and van der Goot, F. G.
(1998)
J. Cell Biol.
140,
525-540[Abstract/Free Full Text]
|
| 27.
|
Hardy, S.,
Kitamura, M.,
Harris-Stansil, T.,
Dai, Y.,
and Phipps, M. L.
(1997)
J. Virol.
71,
1842-1849[Abstract]
|
| 28.
|
Dupree, P.,
Parton, R. G.,
Raposo, G.,
Kurzchalia, T. V.,
and Simons, K.
(1993)
EMBO J.
12,
1597-1605[Medline]
[Order article via Infotrieve]
|
| 29.
|
Li, S.,
Galbiati, F.,
Volonte, D.,
Sargiacomo, M.,
Engelman, J. A.,
Das, K.,
Scherer, P. E.,
and Lisanti, M. P.
(1998)
FEBS Lett.
434,
127-134[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Kurzchalia, T. V.,
and Parton, R. G.
(1996)
FEBS Lett.
389,
552-554
|
| 31.
|
Parton, R. G.,
Joggerst, B.,
and Simons, K.
(1994)
J. Cell Biol.
127,
1199-1215[Abstract/Free Full Text]
|
| 32.
|
van't Hof, W.,
and van Meer, G.
(1994)
in
Cell Lipids: From Synthesis to Cell Biology
(Hoekstra, D., ed), Vol. 40
, pp. 539-563, Academic Press, Orlando, FA
|
| 33.
|
Rodriguez-Boulan, E.,
and Nelson, W. J.
(1989)
Science
245,
718-725[Abstract/Free Full Text]
|
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.